Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celldex Sinks As Lead Asset Rintega Fails In Phase III

This article was originally published in Scrip

Executive Summary

Celldex Therapeutics Inc.'s stock was cut by more than half to $3.79 per share after the company revealed that it would discontinue the Phase III clinical trial known as ACT IV for the cancer vaccine Rintega (rindopepimut) based on an interim assessment of survival for glioblastoma (GBM) patients.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC064687

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel